23.3 C
New York
Thursday, September 23, 2021

Here is why NLS Pharmaceutics AG (NLSP) stock rallied on Friday

NLS Pharmaceutics AG (NLSP) stock soared 107.45% on Friday, March 12, 2021, and it just lost 2.74% in the pre-market session of today March 15, 2021, as of this writing. Let see what was the reason behind such a high peak.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


NLSP License agreement with Novartis

The NLSP stock doubled in value after the company announced that it has entered into a license agreement with Novartis Pharma AG, whereby the Company has obtained, on an exclusive basis in the United States for Sanorex® (mazindol).

Sandoz developed Sanorex as an immediate-release obesity drug designed to reduce weight at a fast pace. NLSP has obtained the same rights on a non-exclusive basis outside the U.S., except for Japan.

Participation is Investor conferences

Earlier the NLSP confirmed that the CEO and Co-Founder of the NLS Pharmaceutics will present the company at Maxim 2021 Emerging Growth Virtual Conference hosted by M-Vest on March 17, 2021. The NLSP’s presentation for this conference will be available on M-Vest following the conference.

Earlier on February 25, 2021, NLSP also participated in Livingston Securities Healthcare and Emerging Growth CEO Series.

Announcement about its IPO

On February 2, 2021, NLSP announced the closing of its initial public offering of 4,819,277 units for $4.15 per unit. NLS received gross proceeds of approximately $20.0 million before any deductions.

About the company:

The company was founded in 2015 and its headquarter is in Switzerland. It’s a clinical-stage pharmaceutical company that is focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders. NLSP major drug Quilience is used for the treatment of narcolepsy. Ronald Hafner is the Chairman of the Board of Directors and Alexander Zwyer is Chief Executive Officer and Director.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.